Gilead Sciences, Inc. $GILD Shares Purchased by Ritholtz Wealth Management

Ritholtz Wealth Management boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 127,453 shares of the biopharmaceutical company’s stock after buying an additional 12,287 shares during the quarter. Ritholtz Wealth Management’s holdings in Gilead Sciences were worth $14,147,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Geode Capital Management LLC grew its stake in shares of Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank purchased a new position in Gilead Sciences in the second quarter valued at $2,150,268,000. Invesco Ltd. raised its stake in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares in the last quarter. Finally, Amundi lifted its holdings in Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after buying an additional 1,614,355 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Rothschild & Co Redburn raised their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Royal Bank Of Canada cut their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set a “sector perform” rating on the stock in a report on Thursday, January 8th. Citigroup boosted their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Scotiabank assumed coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price for the company. Finally, HSBC lifted their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $133.16.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the transaction, the chief financial officer directly owned 153,503 shares in the company, valued at $18,727,366. This represents a 1.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 130,757 shares of company stock worth $16,205,752. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 2.3%

Shares of NASDAQ:GILD opened at $121.26 on Friday. Gilead Sciences, Inc. has a 1-year low of $90.82 and a 1-year high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market cap of $150.44 billion, a P/E ratio of 18.80, a P/E/G ratio of 0.65 and a beta of 0.33. The firm has a fifty day moving average price of $123.24 and a 200 day moving average price of $117.92.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the business posted $2.02 earnings per share. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.